Armata Pharmaceuticals Receives $2.5M DoD Funding for Phase 3 Trial

Armata Pharmaceuticals announced receiving $2.5 million in non-dilutive funding from the Department of Defense to support clinical development of AP-SA02 for antibiotic-resistant infections. The award enhances the company's cash position and bolsters the path to regulatory approval for a critical unmet medical need.